AstraZeneca Pharma India shares may be in focus after the company announced a second brand partnership with Sun Pharma to expand nationwide access to Sodium Zirconium Cyclosilicate (SZC), a therapy for managing hyperkalemia. Under the agreement, both companies will promote, market and distribute SZC under separate brands to accelerate patient access to what AstraZeneca calls an innovative, effective treatment.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets